Welcome Message

We welcome you to the "42^nd World Conference on Lung Diseases & Pulmonology, October 03-04, 2022 in London, U.K.

"Our Conference will provide a unique opportunity to Pulmonologist and physicians to share their research and experiences with the leaders in their fields.The program includes keynote speeches from internationally renowned scientists.Each of these speakers helped to shape the modern concepts. In addition, there will be sessions for oral and poster presentations.Presentations in these sessions will provide an overview of the cutting-edge technologies being used to address difficulties and challenges due to COVID-19.

This conference will be the awesome opportunity for educators, young researchers and also for changing ideas and innovative methods of treatments.

About Conference

Conference Series welcomes all the participants globally to join the global conference “42^nd World Conference on Lung Diseases & Pulmonology” going to be held on October 03-04, 2022 in London, U.K. Lung diseases 2022 gives an Excellence Overview on the related topics and cordially invite all the participants from Public Health Professionals and Community Health Educators, Lung Diseases Associations, Doctors, Healthcare Professionals to interact with Experienced and well qualified people to explore their excellence.

Aim:

As we all are aware of devastation caused by Covid-19 throughout the world. We have faced many causalities and serious medical issues due to this deadly virus. Our conference aims to bring bright minds from all over world in order to share their experiences, challenges and new innovative ideas to overcome from this devastation and bring humanity back on the track.

Why to Attend?

• Sessions on all the latest innovations on particular areas
• Young research forum
• Poster competition
• Exhibitor presentation
• Video presentation
• Exposure to new innovations and researches of their respective fields
• Global networking
• Novel techniques to benefit your research
• Accepted abstracts will be published in the respective journals.

 Target Audience:

• Lung cancer Surgeons
• Respiratory physicians
• Environmental and Occupational Health
• Lung Diseases Associations
• Lung & Respiratory associations
• Public Health Professionals and Community Health Educators
• Pulmonologists
• Pharmacologists
• University Professors
• Doctors
• Nurses
• Directors of Association and Societies
• Infectious Disease Associations
• Health Care Experts
• Research Institution
• Young Research Fellows
• Academic students

Abstract Submission

Abstract Submission Guidelines:

• Abstract length must not exceed 300 words.
• The title should be in sentence case.
• Mention the full name of the author and co-authors (if any) along with affiliation.
• It should contain short biography of the author (limited to 100 words) along with the photograph.
• All the abstracts will be reviewed by the scientific committee members and you will get an email within 24-48 hours after submission of your abstract.
• All the accepted abstracts will be published in the conference proceedings in the respective Journal.

Abstract Submission Link: https://lung-diseases.insightconferences.com/abstract-submission.php

Registration Link: https://lung-diseases.insightconferences.com/registration.php

Email at: lungdiseases@healthconferences.org

Sessions & Tracks

Track 1: Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease is a progressive disease that causes airflow blockage and problems related to breathing. It can cause coughing that produces large amounts of a slimy substance called mucus, wheezing, shortness of breath as well as chest tightness. Cigarette smoking is the leading cause of COPD. Long-term exposure to various lung irritants such as air pollution, chemical fumes, or dusts also contribute to COPD. A rare genetic condition called alpha-1 antitrypsin (AAT) deficiency can also lead to COPD. COPD cannot be cured but it can be treated to lower the chance of complications, and generally improve quality of life. Clinical symptoms and signs, such as abnormal shortness of breath and increased forced expiratory time, can be used to help with the diagnosis of COPD. Various forms of treatment include Medications, supplemental oxygen therapy and surgery.

Track 2: Severe Acute Respiratory Syndrome (SARS)

Severe acute respiratory syndrome (SARS) is a viral respiratory disease caused by a SARS-associated coronavirus. It was first identified at the end of February 2003 during an outbreak that emerged in China and spread to 4 other countries. WHO co-ordinated the international investigation with the assistance of the Global Outbreak Alert and Response Network (GOARN) and worked closely with health authorities in affected countries to provide epidemiological, clinical and logistical support and to bring the outbreak under control. SARS is an airborne virus and can spread through small droplets of saliva in a similar way to the cold and influenza.

Track 3: Respiratory Diseases

Respiratory diseases encompass a variety of pathogenic conditions that affect respiration in living organisms. Respiration involves gas exchange in higher organisms. Respiratory disorders occur in the respiratory tract, which includes the alveoli, bronchi, bronchioles, pleura, pleural cavity, trachea and the nerves and muscles of breathing. Respiratory diseases or lung diseases include COPD, asthma, cystic fibrosis, emphysema, lung cancer, interstitial lung disease, mesothelioma, pulmonary hypertension, tuberculosis, alpha-1 antitrypsin deficiency, bronchiectasis, idiopathic pulmonary fibrosis, pneumonia, respiratory failure, respiratory distress syndrome, sarcoidosis, sleep apnea, sleep deprivation and deficiency, influenza and many more. If left untreated, they lead to health complications and life-threatening conditions.

Track 4: Effect of COVID-19 on Lungs

COVID-19 is a respiratory disease which causes a range of breathing problems, from mild to critical. Older adults and people who have other health conditions like heart disease, cancer, and diabetes may have more serious symptoms when compared to others. Coronavirus can infect the upper or lower part of the respiratory tract and travels down the airways making the lining become irritated and inflamed. In some cases, the infection can reach all the way down into the alveoli. Respiratory inflammation can be observed on a chest X-ray or CT scan. Currently, convalescent plasma from a recovered patient is given by transfusion to a patient who is suffering from COVID-19. The donor antibodies may help the patient fight the illness, possibly shortening the reducing the severity of the disease.

Track 5: COVID-19 Treatment and Recovery

Many individuals, including those who live with chronic lung disease, are at high risk for severe illness if they get sick with COVID-19. In this case, your doctor may recommend you receive an investigational treatment, monoclonal antibodies, which can help your immune system fight off the virus, so you are less likely to get severely ill. If you have stayed home due to illness from confirmed or suspected COVID-19 you should follow the guidance of your healthcare provider and local health department on when to end home isolation. Multiple factors are taken into account in determining when it is safe for you to return to work or emerge from self-quarantine.

Remdesivir, an antiviral which has been shown to shorten the recovery time needed in some hospitalized patients.

Dexamethasone, a corticosteroid used to prevent or reduce inflammation in hospitalized patients with severe illness who need supplemental oxygen.

Tocilizumab or baricitinib, biological therapy used to reduce inflammation in hospitalized patients with severe illness requiring oxygen delivery through a high-flow device, invasive mechanical ventilation or ECMO, if used in addition to dexamethasone.

Track 6: Clinical management of severe acute respiratory infection

A person with an acute respiratory infection, which may include history of fever or measured fever (≥ 38 °C, 100.4 °F) and cough; AND suspicion of pulmonary parenchymal disease (e.g. pneumonia or ARDS), based on clinical or radiological evidence of consolidation and not already explained by any other infection or aetiology, including all clinically indicated tests for community-acquired pneumonia according to local management guidelines. It is not necessary to wait for test results for other pathogens before testing for novel coronavirus. Adolescent or adult patient with fever or suspected infection, cough, respiratory rate > 30 breaths/min, severe respiratory distress, oxygen saturation (SpO2 ) < 90% on room air.

Track 7: Covid19 Vaccine and Lung Immunopathology

As an expanded number of coronavirus vaccines enter human clinical trials, in addition to understanding their efficacy in preventing severe SARS-CoV-2-related disease, a key outcome that will be receiving outsized scrutiny will be whether these vaccines contribute to lung immunopathology upon natural viral infection. Since the emergence of life-threatening severe acute respiratory syndrome (SARS) almost 20 years ago and subsequently Middle East respiratory syndrome (MERS) in 2012, numerous vaccines have been developed and tested in experimental animals to combat these lethal coronavirus-associated respiratory syndromes. An unexpected and concerning feature of several of these is the appearance of lung immunopathology that is seen in animals receiving certain types of vaccines. This result is especially concerning given that vaccine associated enhanced respiratory disease (VAERD) was seen in human vaccine trials against the ubiquitous airway pathogen respiratory syncytial virus (RSV).

Track 8: Innate Immunity and Lung Fibrosis

The immune system protects the body from disease. Over the past decade, however, researchers have come to understand that the innate immune system — the part of the immune system that serves as the body’s first line of defense — is implicated in an enormous number of disease processes that affect many millions of people around the world. Pulmonary fibrosis is a group of serious lung diseases that affect the respiratory system. Pulmonary fibrosis scars and thickens lung tissue. It impacts the connecting tissue in the lung and the alveoli (air sacs inside the lungs). The lung damage gradually gets worse over time.

Track 9: Investigational Drugs and Other Therapies in the treatment of Respiratory Disease

Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. It was initially reported to the World Health Organization (WHO) on December 31, 2019. On January 30, 2020, the WHO declared the COVID-19 outbreak a global health emergency. On March 11, 2020, the WHO declared COVID-19 a global pandemic, its first such designation since declaring H1N1 influenza a pandemic in 2009. Utilization of programs established by the FDA to allow clinicians to gain access to investigational therapies during the pandemic has been essential. The expanded access (EA) and emergency use authorization (EUA) programs allowed for rapid deployment of potential therapies for investigation and investigational therapies with emerging evidence

Track 10: Cardiopulmonary Disorders

The term cardiopulmonary disease describes a range of conditions that affect the heart and lungs. These organs are closely connected, and a problem in one can spill over to the other. For example, when the heart is not able to pump blood efficiently, normal oxygen movement in the lungs is reduced, causing shortness of breath. On the other hand, a problem with the lungs can cause the heart to have to work harder to get oxygen from the lungs into the blood.

Common types of this disease include:

• Chronic bronchitis

• Chronic obstructive pulmonary disease (COPD)

• Congestive heart failure

• Emphysema

Track 11: Tuberculosis

Tuberculosis (TB) is a serious infectious disease that mainly affects the lungs and it is caused by bacteria (Mycobacterium tuberculosis). The bacteria responsible for tuberculosis are spread from one person to another through tiny droplets released into the air via cough and sneeze. Tuberculosis can be fatal when it is untreated. Untreated active disease typically affects the lungs, and it can spread to other parts of the body through the blood stream. Complications of tuberculosis include spinal pain, joint damage, swelling of the membranes that cover the brain, liver or kidney problems and heart disorders. People diagnosed with active TB disease generally have to take a combination of medications for six to nine months. A significant number of TB patients develop post tubercular airway disease or TB-associated COPD.

Track 12: Lung cancer

Lung cancer is a type of cancer that begins in the lungs. Your lungs are two spongy organs in your chest that take in oxygen when you inhale and release carbon dioxide when you exhale. Lung cancer is the leading cause of cancer deaths worldwide. People who smoke have the greatest risk of lung cancer, though lung cancer can also occur in people who have never smoked. The risk of lung cancer increases with the length of time and number of cigarettes you've smoked. If you quit smoking, even after smoking for many years, you can significantly reduce your chances of developing lung cancer.

Track 13: Asthma

Asthma is a clinical syndrome of chronic airway inflammation characterized by recurrent and reversible airway obstruction. Most people with asthma will not develop COPD; however, it’s possible to have both. Asthma-COPD overlap syndrome (ACOS) occurs when someone has these two diseases at a time. Signs of ACOS include difficulty in breathing, wheezing, frequent coughing, excess phlegm, feeling tired, low physical tolerance for exercise, shortness of breath during routine activities. Common triggers for asthmatic symptoms include exposure to allergens (dust mites, cockroach, molds and pollens), exercise and viral infections. Most people who have asthma are treated with daily medicine, called long-term control medicines, along with inhalers containing medicine for short-term relief.

Track 14: Pnemonia

Pneumonia is an infection that inflames the air sacs in the lungs and people with COPD are more likely to develop pneumonia. It is most serious for infants, young children and older people whose age is above 65, and people with weakened immune systems. Bacterial pneumonia, is the most common form, tends to be more serious than other types of pneumonia. The symptoms of bacterial pneumonia can develop gradually. In few cases pneumonia can be difficult to diagnose because the symptoms are so variable and are often very similar to those seen in a cold or influenza. Complications of pneumonia are as follows: pleural effusion, empyema, lung abscess, bacteremia, septicemia, meningitis, septic arthritis, endocarditis, or pericarditis.

Track 15: Sleep Apnea

Sleep apnea is a sleep disorder that occurs when a person's breathing is interrupted during sleep. If left untreated, sleep apnea can increase the risk of health problems, such as high blood pressure, stroke, heart failure, irregular heartbeats, and heart attacks, diabetes, depression, worsening of ADHD, headaches. Depending on the cause and the level of apnea, there are different methods of treatment and the goal of treatment is to normalize breathing during sleep. Treatment options for obstructive sleep apnea include: Continuous Positive Airflow Pressure (CPAP), other breathing devices, oral appliances, implants and surgery.

Track 16: Cystic Fibrosis

Cystic fibrosis is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time and it affects the cells that produce mucus, sweat and digestive juices. It is caused by a change, or mutation, in a gene called CFTR (cystic fibrosis transmembrane conductance regulator). This gene controls the flow of salt and fluids in and out of the cells. The thick and sticky mucus associated with cystic fibrosis clogs the tubes that carry air in and out of the lungs. This can cause signs and symptoms such as persistent cough that produces thick mucus, wheezing, breathlessness, exercise intolerance, repeated lung infections, inflamed nasal passages or a stuffy nose. Cystic fibrosis is one of the leading causes of bronchiectasis, a condition that damages the airways and this makes it harder to move air in and out of the lungs and clear mucus from the airways.

Track 17: Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive disease isolated to the lung. IPF is a type of interstitial lung disease, which is a group of 200 diseases with similar symptoms but different causes. Symptoms of Idiopathic pulmonary fibrosis develop gradually and may not be noticed until the disease is well-established. IPF affects each person differently and the disease progresses at varying rates and it primarily involves the interstitium (the tissue and space around the air sacs of the lungs) and does not affect the airways or blood vessels directly.

Track 18: Alpha 1 Antitrypsin Deficiency & COPD

Alpha-1 antitrypsin deficiency is a genetic disorder that is passed on in families and affects the lungs, liver and skin. When this condition affects the lungs, it causes COPD. There is no cure, but treatment can help people with Alpha-1 antitrypsin deficiency manage their symptoms and live a better life. The preliminary symptoms are shortness of breath following mild activity, reduced ability to exercise, and wheezing. Other signs and symptoms include unintentional weight loss, recurring respiratory infections, fatigue, and rapid heartbeat upon standing. Affected individuals often develop emphysema, which is a lung disease caused by damage to the small air sacs in the lungs. Alpha-1 antitrypsin deficiency accounts for 1 to 2% of all cases of chronic obstructive pulmonary disease.

Track 19: Pathology and Clinical Management of COPD

The predominant pathologic changes of COPD are found within the airways; however, changes are seen within the lung parenchyma and pneumonic vasculature. In an individual, the pattern of pathologic changes depends on the underlying illness (e.g., bronchitis, emphysema, alpha-1 antitrypsin deficiency), presumably individual susceptibility, and illness severity. High resolution computerized axial tomography can assess lung parenchyma, airways, and pneumonic vasculature. About 62 % of patients with moderate to severe COPD report variability in symptoms (e.g., dyspnea, cough, sputum, wheezing, or chest tightness) over the course of the day or week-to-week; morning is usually the worst time of day. An effective COPD management objective includes four components: assess and monitor the disease; reduce the risk factors; manage and stabilize COPD; manage the exacerbations. The most important factor for the COPD is cigarette smoking. The clinical management techniques involved to reduce the exacerbation of these factors that affect COPD must be developed in an efficient way.

Track 20: Pulmonary Rehabilitation

Pulmonary Rehabilitation is an exclusive program for education and exercise that helps to manage the breathing problems, increase the alveolar capacity for breathing and the energy of the individual and reduces the breathlessness. Pulmonary rehabilitation can help to gain strength, reduce symptoms of anxiety or depression, and make it easier to manage routine activities, work, and outings or social activities.

Track 21: Genetic risk factor of COPD

Even if an individual has never smoked or been unprotected to pollutants for an extended period, they can still develop COPD. Alpha-1 Antitrypsin Deficiency (AATD) is the most commonly known genetic risk factor of COPD in emphysema. Alpha-1 Antitrypsin related COPD is caused by a deficiency of the Alpha-1 in the bloodstream. Without the Alpha-1 Antitrypsin protein, white blood cells begin to harm the lungs and lung deterioration occurs. The World Health Organization and the American Thoracic Society suggests that everyone determined to have COPD be tested for Alpha-1.

Track 22: Diagnosis and Treatment of COPD

The main test for diagnosing COPD is a lung function test called spirometry which involves the use of a machine called a spirometer that measures how much air you are able to move by taking a deep breath in and out, and how quickly you are able to do so. Arterial blood gas analysis is second important test in diagnosing COPD. This test measures how much oxygen and carbon dioxide are present in the blood. A high percentage of carbon dioxide in the blood can be a sign of poorly functioning lungs. The important methods of treatment are pharmacotherapy and smoking cessation, while pulmonary rehabilitation, long-term oxygen therapy, and surgery may be considered in selected patients. Steroids, inhalers and antibiotics may be prescribed to treat various symptoms of COPD. Smoking cessation is the most effective intervention in stopping the progression of COPD, as well as increasing survival rate of persons suffering with COPD. Hence, smoking cessation should be the top priority in the treatment of COPD.

Track 23: Digital Health in Respiratory Care

Everyday life is increasingly influenced by digitization. Digital health technology promises to facilitate a patient-centered care model for the management of COPD by empowering patients to self-manage effectively and presently, it is not widely used in medicine. For pulmonology, digitization offers opportunities and risks in different areas like obstructive lung diseases, thoracic oncology, pulmonary rehabilitation, sleep medicine, home mechanical ventilation, and in intensive care medicine. One of the opportunities is that the use of new technologies such as medical apps and the analysis of this new support make it possible to better understand and manage diseases. One of the key advantages is the use of "big data" for displaying dynamic behavior to better understand disease processes, and to optimize patient management by using analytic techniques such as machine learning. Risks to be considered are data privacy and security as well as the use of artificial intelligence. Strategies used to date include approaches to monitoring and improving adherence, such as electronic inhalers, text messaging and reminders, and self-management tools.

Track 24: Lung Cancer Diagnosis & Treatment

Lung cancer is a condition that causes cells to divide in the lungs uncontrollably which leads to the growth of tumors that reduce a person's ability to breathe. Symptoms of lung cancer include appetite loss, changes to a person's voice, such as hoarseness, frequent chest infections, such as bronchitis or pneumonia, lingering cough that may start to get worse, shortness of breath, unexplained headaches, weight loss and wheezing. Early diagnosis of lung cancer can be lifesaving because lung cancer cells can travel to other areas of the body before a doctor detects them in the lungs. If metastasis has taken place, it makes treating the disease much more difficult. Treatment for lung cancer depends on its location and stage, as well as the overall health of the individual. Possible treatments include surgery, chemotherapy, radiation therapy and targeted therapy.

Track 25: Depression and anxiety in COPD

Depression and anxiety in COPD are regular in patients with chronic obstructive pulmonary disease (COPD), assessments of their pervasiveness differ significantly. These likely reflect the assortment of scales and strategies used to measure such symptoms. Patients with COPD with three or more comorbidities are more likely to be frequently hospitalized and may die prematurely compared to COPD patients without comorbidities.  An uplifted experience of dyspnoea is probably contributing component to anxiety. Feelings of depression may be precipitated by the loss and grief associated with the disability of COPD. Smoking has been associated with nicotine addiction, and the factors that contribute to smoking may also predispose to anxiety and depressive disorders. The cause of depression and anxiety symptoms are multifactorial and include behavioural, social and biological factors. Lung Conferences exhibits randomized controlled trials show that activity exercise training and precisely chose pharmacological treatment are regularly effective in ameliorating anxiety and depression.

Market Analysis

Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung manifest due to the narrowing of bronchi which often cause excessive contraction of smooth muscles. The major types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Increase in prevalence of COPD and asthma patients, rising geriatric population, increase in pipeline products, growing government and non-government initiatives for spreading awareness are the major factors driving the growth of the global obstructive lung diseases market.

Globally, asthma and COPD are one of the leading chronic respiratory diseases, with high prevalence and increasing health care and economic burden. They are either genetically acquired or caused due to several environmental factors. The global market for Asthma & COPD has been analyzed based on drugs and devices which are used for these diseases. Currently, North America leads the global market for asthma & COPD drugs and devices, and it was followed by Europe in terms of market capitalization. Growing aging population along with increasing automotive and industrial exhaust gases have remained the key drivers for the global asthma and COPD market. Degrading air quality near the industrial areas has led to the increased incidence of asthma in the low-income population in the emerging economies of China, India, Brazil and Russia.

COPD is rated to be the fourth most common cause of mortality, and expected to reach third position by 2030, in case the risks such as smoking, pollution is not addressed. There is a rise in the prevalence of asthma and COPD in both developed and developing countries. In developed countries, the rise in prevalence is mainly due to lifestyle change such as smoking, while in developing countries rise is observed due to presence of most polluted cities in the world and inclusion of smoking in day-to-day lifestyle. Global COPD drugs market size will grow by almost USD 3.52 billion during 2019-2023, at a CAGR close to 4% due to the success of combination therapies.

As per the Global Burden of Disease study, it is estimated that chronic obstructive pulmonary disease caused 3.2 million deaths globally in 2015. Disease burden due to COPD was the highest in India, Nepal, Papua New Guinea, and Lesotho. COPD manifests itself as an occupational hazard in people working in agriculture, mining, plastics, and other industries.

Governments across each country have implemented regulations for the production, standardization, and utilization of COPD devices. These devices are divided into categories –Class-I, Class-II, Class-III, and Class-IV, depending upon the level of risk associated.

However, stringent government regulatory requirement for the approval of asthma and COPD drugs, side effects associated with the drug treatment, and patent expiry of drugs restrict the market growth.

The global market of obstructive lung disease is expected to grow at a CAGR of approximately 8.5% during the forecast period 2017-2023.

Intended Audience

• Obstructive Lung Disease Drug Suppliers
• Obstructive Lung Disease Drug Manufacturers
• Obstructive Lung Disease Device Suppliers
• Obstructive Lung Disease Device Manufacturers
• Research And Development (R&D) Companies
• Medical Research Laboratories
• Academic Medical Institutes and Universities

Segmentation

The obstructive lung disease is segmented on the basis of disease type, product type, drug class, route of administration and end-users.

On the basis of disease type, the market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others 

On the basis of product type market is segmented into inhalers, and nebulizers and others. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs) and others. Moreover the nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers

On the basis of drug class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the Combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.

On the basis of route of administration, market is segmented into oral, inhaler, intravenous, subcutaneous, and others

On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

Key Players

The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players.

Some of key the players in the global obstructive lung disease market are GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. Inc. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (U.K), Pfizer Inc. (U.S), Mylan (U.S.), Aerovance Inc. (U.S.), Alkermes Inc. (U.S.),  Almirall SA. (U.S.), Genentech Inc. (U.S.), Sepracor, Inc. (U.S.), Skyepharma plc (U.S.).

Regional Analysis

The global obstructive lung disease market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The Americas is projected to hold the largest share of the global obstructive lung disease market due to presence of superior research and development base, strong regional economics, and greater emphasis on disease prevention and wellness by governments.

The European obstructive lung disease market is expected to witness rapid growth owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.

Countries such as China, Japan, and India in Asia Pacific are also poised to be promising markets for obstructive lung disease in the near future. The healthcare expenditure in Asia increased due to an extension of state healthcare programs and the increasing affluence of the population. India is anticipated to witness an expansion in spending due to a government resolution to enhance healthcare services. Moreover, China and South Korea are trying to develop their biotechnology sector for diagnosis purpose. China’s efforts to develop its biotech sector has shown good results in sectors such as vaccines and biological products and the same can be expected in the obstructive lung disease industry. However, low research and development (R&D) yields, high infrastructure cost, stringent regulatory framework are some of the restraints of the obstructive lung disease market.

The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.

YRF (Young Research Forum)

YRF (Young Research Forum)

Prestigious Award for Young Research’s at Lung Diseases 2022 – “Coronavirus and the outbreak of the respiratory illness”

Lung Diseases 2022 Committee is glad to announce “42nd World Conference on Lung Diseases & Pulmonology” on October 03-04, 2022 in London, U.K focusing on the theme: “Coronavirus and the outbreak of the respiratory illness” Lung Diseases 2022 developments are maintaining their momentum. Lung Diseases program delves into strategic discussions.

Lung Diseases 2022 Young Scientist Awards:

Lung Diseases 2022 Committee is intended to honour prestigious award for talented Young researchers, scientists, Young Investigators, Post-Graduate students, Post-doctoral fellows, Trainees, Junior faculty in recognition of their outstanding contribution towards the conference theme. The Young Scientist Awards make every effort in providing a strong professional development opportunity for early career academicians by meeting experts to exchange and share their experiences on all aspects of COPD and lung diseases.`

Young Research’s Awards at Lung Diseases 2022 for the Nomination: Young Researcher Forum - Outstanding Masters/Ph.D./Post Doctorate thesis work Presentation, only 25 presentations acceptable at Lung Diseases 2022 young research forum. 

Benefits

• Young Scientist Award recongination certificate and memento to the winners.

• Our conferences provide best Platform for your research through oral presentations.

• Learn about career improvement with all the latest technologies by networking.

• Young Scientists will get appropriate and timely information by this Forum.

• Platform for collaboration among young researchers for better development.

• Provide an opportunity for research interaction and established senior investigators across the globe in the field.

• Share the ideas with both eminent researchers and mentors.

• It’s a great privilege for young researchers to learn about the research areas for expanding their research knowledge. 

Eligibility

• Young Investigators, Post-Graduate students, Post-doctoral fellows, Trainees, Junior faculty with a minimum of 5 years of research experience

• Presentation must be into scientific sessions of the conference.

• Each Young Researcher / Young Scientist can submit only one paper (as first author or co-author).

• Age limit-Under 35yrs

• All submissions must be in English.